Effects of dapaglifrogine and metoformine in patients with type 2 diabetes:a randomized controlled study
- Conditions
- Type 2 diabetes
- Registration Number
- JPRN-UMIN000032296
- Lead Sponsor
- Yokohama City University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Not provided
1)Patients diagnosed with Type 1 diabetes or secondary forms of diabetes 2)Patients with renal dysfunction (eGFR <45ml/min/1.73m2) 3)Patients with hepatic dysfunction(AST and/or ALT >3X upper limit of normal) 4)Patients with severe congestive heart failure, acute heart failure 5)Patients who are taking steroid medication 6) Patients with a history of diabetic ketoacidosis, diabetic coma during the last 6 months 7)Patients with active malignant neoplasm 8)Patients with severe infection or injury 9)Patients with hypersensitivity to metoformine or dapaglifrogine 10) Patients who are pregnant,lactating or willing to be pregnant during this study 11) Patients who have taken SGLT2 or metoformine within 8 weeks prior to enroll, or who are already taking SGLT2 or metoformine 12)Patients who are unable to obtain informed consent to this study 13)Patients who are inadequacy of using this therapy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The improvement in HbA1c after 24 weeks of treatment.
- Secondary Outcome Measures
Name Time Method